Vanos is a drug owned by Bausch Health Us Llc. It is protected by 4 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 09, 2023. Details of Vanos's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8232264 | Compositions and methods for enhancing corticosteroid delivery |
Mar, 2023
(2 years ago) |
Expired
|
| US7220424 | Compositions and methods for enhancing corticosteroid delivery |
Jan, 2023
(2 years ago) |
Expired
|
| US7794738 | Compositions and methods for enhancing corticosteroid delivery |
Sep, 2022
(3 years ago) |
Expired
|
| US6765001 | Compositions and methods for enhancing corticosteroid delivery |
Dec, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Vanos's patents.
Latest Legal Activities on Vanos's Patents
Given below is the list of recent legal activities going on the following patents of Vanos.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Maintenance Fee Reminder Mailed
Critical | 18 Mar, 2024 | US8232264 (Litigated) |
| Expire Patent
Critical | 17 Oct, 2022 | US7794738 (Litigated) |
| Maintenance Fee Reminder Mailed
Critical | 02 May, 2022 | US7794738 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 02 Jan, 2020 | US8232264 (Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Oct, 2018 | US7220424 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Feb, 2018 | US7794738 (Litigated) |
| Patent Issue Date Used in PTA Calculation
Critical | 31 Jul, 2012 | US8232264 (Litigated) |
| Recordation of Patent Grant Mailed
Critical | 31 Jul, 2012 | US8232264 (Litigated) |
| Email Notification
Critical | 12 Jul, 2012 | US8232264 (Litigated) |
| Issue Notification Mailed
Critical | 11 Jul, 2012 | US8232264 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but
Vanos is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Vanos's family patents as well as insights into
ongoing legal events
on those patents.
Vanos's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vanos's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 09, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vanos Generic API suppliers:
Fluocinonide is the generic name for the brand Vanos. 23 different companies have already filed for the generic of Vanos, with Sun Pharma Canada having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vanos's generic
How can I launch a generic of Vanos before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Vanos's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Vanos's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Vanos -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 0.001 | 31 Jan, 2008 | 1 | 14 Jan, 2014 | 21 Dec, 2021 | Eligible |
About Vanos
Vanos is a drug owned by Bausch Health Us Llc. It is used for relieving inflammation and itching in dermatological conditions amenable to corticosteroid treatment in patients 12 years and older. Vanos uses Fluocinonide as an active ingredient. Vanos was launched by Bausch in 2005.
Approval Date:
Vanos was approved by FDA for market use on 11 February, 2005.
Active Ingredient:
Vanos uses Fluocinonide as the active ingredient. Check out other Drugs and Companies using Fluocinonide ingredient
Treatment:
Vanos is used for relieving inflammation and itching in dermatological conditions amenable to corticosteroid treatment in patients 12 years and older.
Dosage:
Vanos is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | CREAM | Prescription | TOPICAL |